Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, IMA

Novogene Europe Launches Clinical Sequencing Services for its European Customers


CAMBRIDGE, England, March 8, 2021 /PRNewswire/ -- Novogene Europe, a leading provider of genomic services and solutions, has announced the launch of a Clinical Service to provide its European customers with next-generation sequencing (NGS) services and solutions for their clinical samples.

The Clinical Service has launched after Novogene's Cambridge Sequencing Centre was awarded IS0/IEC 17025 accreditation, the highest recognised quality standard in the world for calibrating and testing laboratories. Accreditation means the lab consistently produces precise and accurate test data and has implemented a rigorous quality management system.

The Cambridge Sequencing Centre ISO/IEC 17025 accreditation follows on from CLIA accreditation for the California Clinical Laboratory in the USA, and CAP accreditation, received in 2017, for the Tianjin Medical Lab in China.

"ISO/IEC 17025 accreditation enables us to expand our European sequencing to include high-quality clinical services," said Dr Aina Pi Roig, Technical Support Supervisor for Clinical Services at Novogene Europe. "Our goal is to become the trusted partner for scientific researchers and genetic testing suppliers through our best-in-class sequencing solutions, great customer service and expert scientific team."

"We're really proud of all the work the Cambridge Sequencing Centre team put in to achieve the ISO/IEC 17025 accreditation. It is testament to the precision and standardisation of our experimental procedures and bioinformatics analysis," added Tingting Zhou, General Manager, Novogene Europe. "Offering clinical services opens up a range of new solutions for our customers and really helps us in our mission to advance genomics and improve life."

About Novogene

Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise. With one of the largest sequencing capacities in the world, we utilise our deep scientific knowledge, first-class customer service and unsurpassed data quality to help clients realise their research goals in the rapidly evolving world of genomics.

With over 2,000 employees, multiple locations around the world, 32 NGS related patents and over 580 publications in top tier journals such as Nature and Science, we have rapidly become a world-leader in NGS services.

Our Sequencing Centre on the Cambridge Science Park offers our customers an unrivalled NGS service with a quick turn-around, exceptional data quality and expert PhD level advice and support throughout your project. 

To find out more about Novogene Europe's Clinical services please visit en.novogene.com or contact [email protected],  +44-1223-628-750

 

SOURCE Novogene Europe


These press releases may also interest you

at 16:20
Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new employees of the Company. The...

at 16:19
The Autorité des marchés financiers ("AMF") cautions Québec consumers about the website dr-hypotheque.ca.  According to information...

at 16:15
Block, Inc. will release financial results for the second quarter of 2024 on Thursday, August 1, 2024, after market close. Block will also host a conference call and earnings webcast at 2:00 p.m. Pacific Time/5:00 p.m. Eastern Time on the same day...

at 16:15
Snap Inc. will hold its quarterly conference call to discuss second quarter 2024 financial results on Thursday, August 1, 2024 at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time). A live webcast and replay of the conference call will be accessible...

at 16:10
bluebird bio, Inc. today announced that the Compensation Committee of the Company's Board of Directors approved an inducement grant of stock options to purchase a total of 300,000 shares of common stock to its chief financial officer, James...

at 16:10
AppLovin Corporation, ("AppLovin" or the "Company") the leading marketing platform, today announced it will report financial results for the second quarter on Wednesday, August 7, 2024 after the U.S. stock market closes. An accompanying webinar...



News published on and distributed by: